QUALITY OF LIFE IN PERIMENOPAUSAL WOMEN WITH CLIMACTERIC SYNDROME TREATED WITH THE PINEAL HORMONE MELATONIN
- Authors: Usoltseva E.N.1
-
Affiliations:
- South Ural State Medical University, Ministry of Health of Russia
- Issue: No 6 (2017)
- Pages: 104-110
- Section: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/329717
- DOI: https://doi.org/10.18565/aig.2017.6.104-10
- ID: 329717
Cite item
Open Access
Access granted
Abstract
Objective. To assess the quality of life in perimenopausal women with climacteric syndrome treated with melatonin. Subjects and methods. Seventy women aged 53.6±5.5 years, who had taken melatonin 3 mg before bedtime for three months, were examined. The investigators evaluated the efficiency of the treatment, by using the Kupperman index, and assessed the quality of life by the SF-36 and WHQ questionnaires before treatment and 1 and 3 months after follow-up. Results. Neuroautonomic, metabolic, endocrine, and psychoemotional symptoms were relieved three months after treatment. The SF-36 data showed that physical functional and role physical functioning were statistically significantly increased, and WHQ indicated a reduction in somatic symptoms, sleep problems, depression, and anxieties/fears. Conclusion. The pineal hormone melatonin is effective in the treatment of mild climacteric syndrome and improves some quality-of-life indices in female women.
Keywords
Full Text
About the authors
Elena Nikolaevna Usoltseva
South Ural State Medical University, Ministry of Health of Russia
Email: elena-usoltseva@yandex.ru
PhD, assistant of Obstetrics and gynecology department of the Additional Professional Education Institute Chelyabinsk 454092, Vorovsky str. 64, Russia
References
- Юренева С.В., Ильина Л.М., Якушевская О.В. Менопаузальная гормональная терапия в постменопаузе: качество жизни сегодня и в долгосрочной перспективе. Гинекология. 2016; 18(1): 24-9.
- Karasek M. Does melatonin play a role in aging processes? J. Physiol. Pharmacol. 2007; 58(Suppl. 6): 105-13.
- Прилепская В.Н., Богатова И.К., Радзинский В.Е. Новое в профилактике и терапии климактерического синдрома. Гинекология. 2016; 18(1): 7-12.
- Иванова О.В., Усольцева Е.Н., Брюхина Е.В. Валидация русскоязычной версии опросника WOMEN’S HEALTH QUESTIONNAIRE (WHQ). Вестник межнационального исследования качества жизни. 2011; 17-18: 58-68.
- Инструкция по обработке данных, полученных с помощью опросника SF-36. Available at: http://www.cpr.spb.ru/question/sf-36_guidelines.rtf
- Колесникова Л.И., Мадаева И.М., Семенова Н.В., Солодова Е.И., Даренская М.А. Антиоксидантная система и процессы липопероксидации у женщин с нарушением сна в постменопаузе. Акушерство и гинекология. 2015; 6: 98-103.
- Анисимов В.Н., Виноградова И.А. Старение женской репродуктивной системы и мелатонин. СПб.: Издательство «Система»; 2008: 44с.
- Гафарова Е.А., Мальцева Л.И. Применение мелатонина в акушерско-гинекологической практике. Гинекология. 2014; 16(6): 25-8.
- Кузнецова И.В., Бурчаков Д.И. Возможности терапии климактерических симптомов с помощью препаратов мелатонина. Гинекология. 2015; 17(5): 44-8.
- Amstrup A.K., Sikjaer T., Mosekilde L., Rejnmark L. The effect of melatonin treatment on postural stability, muscle strength, and quality of life and sleep in postmenopausal women: a randomized controlled trial. Nutr. J. 2015; 14: 102. doi: 10.1186/s12937-015-0093-1.
- Kotlarczyk M.P., Lassila H.C., O'Neil C.K., D’Amico F., Enderby L.T., Witt-Enderby P.A. et al. Melatonin osteoporosis prevention study (MOPS): a randomized, double-blind, placebo-controlled study examining the effects of melatonin on bone health and quality of life in peri-menopausal women. J. Pineal Res. 2012; 52(4): 414-26. doi: 10.1111/ j.1600-079X.2011.00956.x.
- Wade A.G., Ford I., Crawford G., McMahon A.D., Nir T., Laudon M. et al. Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr. Med. Res. Opin. 2007; 23(10): 2597-605. doi: 10.1185/030079907X233098.
- Wade A.G., Ford I., Crawford G., McConnachie A., Nir T., Laudon M. et al. Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med. 2010; 8: 51. doi: 10.1186/1741-7015-8-51.
- Леваков С.А., Боровкова Е.И. Возможности применения мелатонина для улучшения качества жизни пациенток с предменструальным и климактерическим синдромом. Consilium medicum. 2015; 6: 11-5.
- Глазунова А.В., Юренева С.В., Ежова Л.С. Вульвовагинальная атрофия: симптомы, влияние на эмоциональное благополучие, качество жизни и сексуальную функцию. Акушерство и гинекология. 2015; 12: 97-102.
Supplementary files
